GlycoNex (4168)

Currency in TWD
25.30
-0.10(-0.39%)
Closed·
4168 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.1525.65
52 wk Range
20.5530.00
Key Statistics
Bid/Ask
33.25 / 33.30
Prev. Close
20.75
Open
25.2
Day's Range
25.15-25.65
52 wk Range
20.55-30
Volume
194.91K
Average Volume (3m)
389.78K
1-Year Change
-9.8039%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4168 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Operates with a moderate level of debt

GlycoNex News & Analysis

Show more
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0.67 / --
Revenue / Forecast
12.05M / --
EPS Revisions
Last 90 days

4168 Income Statement

Compare 4168 to Peers and Sector

Metrics to compare
4168
Peers
Sector
Relationship
P/E Ratio
−10.7x−12.2x−0.4x
PEG Ratio
0.350.140.00
Price/Book
3.1x6.8x2.6x
Price / LTM Sales
78.3x144.4x3.0x
Upside (Analyst Target)
-243.6%58.1%
Fair Value Upside
Unlock−34.0%8.3%Unlock

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company’s pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various solid tumor types, such as colorectal, gastric, lung, breast, and pancreatic cancers; GNX1021, an antibody–drug conjugate that has completed the preclinical stage for oncology indications; GNX201-ADC, an antibody drug in the preclinical stage for the treatment of solid tumors; and GNX203, a glycan-directed antibody drug currently in the lead optimization stage for the treatment of solid tumors, including pancreatic, colorectal, and gynecologic cancers. In addition, the company offers technical consulting services for antibody manufacturing; and general investment services. It has a collaboration with Mitsubishi Gas on the development of denosubmab biosimilar SPD8. GlycoNex Incorporation was incorporated in 2001 and is based in New Taipei City, Taiwan.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
527.03K0.47%13.33M
Other Institutional Investors
8.50M7.56%215.12M
Public Companies & Retail Investors
103.49M91.97%2.62B
Total
112.52M100.00%2.85B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Taiwan Advance Bio-Pharmaceutical Inc.2.84%3,192,68880,775
Otsuka Holdings Co., Ltd.2.70%3,036,00076,811

FAQ

What Is the GlycoNex (4168) Stock Price Today?

The GlycoNex stock price today is 25.30 TWD.

What Stock Exchange Does GlycoNex Trade On?

GlycoNex is listed and trades on the Taipei Exchange.

What Is the Stock Symbol for GlycoNex?

The stock symbol for GlycoNex is "4168."

What Is the GlycoNex Market Cap?

As of today, GlycoNex market cap is 2.85B TWD.

What Is GlycoNex's Earnings Per Share (TTM)?

The GlycoNex EPS (TTM) is -2.42.

From a Technical Analysis Perspective, Is 4168 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GlycoNex Stock Split?

GlycoNex has split 4 times.

What is the current trading status of GlycoNex (4168)?

As of Jun 20, 2026, GlycoNex (4168) is trading at a price of 25.30 TWD, with a previous close of 20.75 TWD. The stock has fluctuated within a day range of 25.15 TWD to 25.65 TWD, while its 52-week range spans from 20.55 TWD to 30.00 TWD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.